Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue SUPPL., 1999, Pages

  Chang, A Y ^a   Hui, L ^a   Asbury, R ^a   Boros, L ^a   Garrow, G ^b   Rubins, J ^a  

^a Interlakes Oncology and Hematology PC   (United States)

^b Genesee Hospital   (United States)

Author keywords

Carboplatin; Etoposide; Ifosfamide; Metastatic breast cancer; Salvage therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA; ANTINEOPLASTIC AGENT; ICE PROTOCOL 3;

ADULT; AGED; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; DRUG RESISTANCE; ENTEROCOLITIS; FEVER; PHASE 2 CLINICAL TRIAL; SEPSIS; BREAST TUMOR; MIDDLE AGED; SAFETY; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASM METASTASIS; SAFETY; SALVAGE THERAPY;

EID: 0033252073     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051113     Document Type: Conference Paper

References (15)

1. Harris JR, Morrow M, Norton L (1997) Malignant tumors of the breast. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, pp 1557-1616
2. Hortobagyi GN (1997) Paclitaxel-based combination chemotherapy for breast cancer. Oncology 11 [Suppl 2]: 29-37
3. Ravdin PM (1995) Taxoids: effective agents in anthracycline-resistant breast cancer. Semin Oncol 22 [Suppl 13]: 229-234
4. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400
5. Hortobagyi GN (1992) Activity of ifosfamide in breast cancer. Semin Oncol 19 [Suppl 12]: 36-42
6. Sanchiz F, Milla A (1990) High-dose ifosfamide and mesna in advanced breast cancer: a phase II study. Cancer Chemother Pharmacol 26: 991-992
7. Becher R, Höfeler H, Kloke O, May D, Wandl U, Niederle N, Richter R, Scheulen ME, Schmidt CG (1991) Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. Oncology 48: 459-463
8. Gad-el-Mawla N, Hamza MR, Zikri ZK, Elserafi M, El-Khodari A, Khaled H, Gafaar R (1990) Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer. Cancer Chemother Pharmacol 26: 85-86
9. Cox EB, Burton GV, Olsen GA, Vugrin D (1989) Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 12: 53-56
10. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DN, Ellison NM, Reuter NF, Nelimark RA (1990) Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer 65: 418-421
11. Vinolas N, Daniels M, Estape J, Grau JJ, Palombo H, Sola C (1992) Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients. Am J Clin Oncol 15: 160-162
12. Martin M, Diaz-Rubio E, Casado A, Santabarbara P, Vega JML, Adroves E, Lenaz (1992) Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 10: 433-437
13. Von Hoff DD (1987) Whither carboplatin? - a replacement or an alternative to cisplatin. J Clin Oncol 5: 169-170
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
15. Fields KK, Zorsky P, Hiemenz JW, Kronish LE (1994) Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol 12: 544-552